Pramipexole (Mirapex)
Non-ergot D3-D2 selective DA agonist. FDA-approved (1997 Boehringer) for Parkinson's + restless legs. AAS-PCT niche: prolactin control + sexual stimulation (D3 selectivity). FDA black-box ICD risk (impulse-control disorder).
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
Related comparisons
Cabergoline vs Bromocriptine vs PramipexoleWHAT IS PRAMIPEXOLE (MIRAPEX)?
Detailed overview
Pramipexole (Mirapex) is a non-ergot dopamine receptor agonist developed by Boehringer Ingelheim and FDA-approved in 1997 for Parkinson's disease and restless legs syndrome (RLS). Unlike cabergoline, it is not ergot-structured, so cardiac valvulopathy risk is negligible. Its unique pharmacological profile is D3 selectivity (D3 > D2, ~7-10× affinity differential) – this drives the sexual-stimulation effect ('RecPharm' off-label libido/orgasm-quality enhancement documented at community level). Through the pituitary D2 effect it lowers prolactin, similar to cabergoline, but is rarely first-line in the AAS-PCT world – for two reasons: (1) FDA black-box warning for impulse-control disorder (ICD) risk (gambling, hypersexuality, compulsive shopping, binge eating) – 17-22% incidence at Parkinson dose (Weintraub 2010 DOMINION study, PMID 20457959), lower at AAS-PCT dose but exists; (2) strict titration dose window (0.0625 mg ultra-low start). Niche use: sexual-emphasis prolactin control + RecPharm sub-community recreational. Tier 3.
Mechanism
Non-ergot D3-D2 selective DA agonist (D3 > D2), pituitary prolactin suppression + sexual stimulation
Dosing (AAS)
0.0625 mg evening start, max 0.25-0.5 mg/day titrated
Half-life
~8-12 hours
Onset
Prolactin reduction 2-4 h
Legal status
FDA + EMA Rx, HU + PL approved, WADA allowed
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Impulse-control disorder (ICD): pathological gambling, hypersexuality, compulsive shopping, binge eating – FDA black-box, dopamine-agonist class effect, warrants discontinuation.
- Sudden sleep attacks and daytime somnolence – driving and operating machinery may be hazardous, especially during titration.
- Orthostatic hypotension: dizziness, lightheadedness on standing, especially at dose initiation – rise slowly.
- Nausea, gastric upset, loss of appetite – common in the first days, mitigated by taking with food.
- Headache, fatigue, lethargy, and occasionally vivid dreams or hallucinations (the latter mainly at higher, Parkinson-level doses).
- Peripheral edema (leg swelling) – a dopamine-agonist class effect to watch for with longer use.
- Dopamine agonist withdrawal syndrome (DAWS) on abrupt discontinuation: anxiety, panic, sweating, pain, dysphoria – taper gradually.
Contraindications · 7
- History of impulse-control disorder or addiction (gambling, OCD-spectrum, hypersexuality) – markedly raises ICD risk, avoid.
- Severe renal impairment (CrCl <30 ml/min) without dose reduction – ~90% is excreted unchanged renally and accumulates.
- Concurrent antipsychotic therapy (D2/D3 antagonists) – direct mechanism conflict, mutually counteracting.
- Metoclopramide / domperidone (D2-antagonist antiemetics) – mechanism conflict, avoid; use a different antiemetic for nausea.
- Pregnancy and breastfeeding – no established safety, and prolactin suppression also inhibits lactation.
- Occupations or activities where sudden sleep onset is critical (professional driving, working at heights) – especially during titration.
- Combining with alcohol or other sedatives – increases somnolence, sleep attacks, and ICD risk.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients (DOMINION study)
Weintraub D, Koester J, Potenza MN, et al.
Effects of acute prolactin manipulation on sexual drive and function in males.
Krüger TH, Haake P, Haverkamp J, Krämer M, Exton MS, Saller B, Mann K, Hartmann U, Schedlowski M
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.
Winkelman JW, Berkowski JA, DelRosso LM, Koo BB, Scharf MT, Sharon D, Zak RS, Kazmi U, Falck-Ytter Y, Shelgikar AV, Trotti LM, Walters AS
Telegram
Have a question about Pramipexole (Mirapex)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.